Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos (PicoS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03386760 |
|
Recruitment Status : Unknown
Verified August 2019 by Centre Hospitalier Universitaire de Nice.
Recruitment status was: Recruiting
First Posted : December 29, 2017
Last Update Posted : August 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The investigators developed an ultra-speed picosecond laser (20ps) with a 20gHz repetition rate that provide very promising results in vitro and in ex vivo skin to remove skin tattoos.
The aim of this study is to evaluate the efficacy and tolerance of a new ultra-speed picosecond laser and to compare it to a nanosecond laser for treating black tattoos.
In a first phase of the study 10 patients with black tattoos will be treated with increasing fluencies of the picosecond laser to the optimal parameters in terms of efficacy and tolerance.
In a second phase, 10 additional subjects with black tattoos will be treated after central randomization on half of the tattoo with the picosecond laser (with the parameters determined in the first phase) and the other half treated with a nanosecond laser.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Tattoo; Pigmentation | Device: Laser Utilisation PicoSecond Device: Laser Utilisation Nano-second | Phase 1 Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos |
| Actual Study Start Date : | January 15, 2018 |
| Estimated Primary Completion Date : | May 2020 |
| Estimated Study Completion Date : | May 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: A- Ultra-Speed Picosecond laser
Utilisation of Ultra-speed Picosecond laser for tattoo depigmentation
|
Device: Laser Utilisation PicoSecond
Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions |
|
Active Comparator: B- Nanosecond laser
Utilisation of Nanosecond laser for tattoo depigmentation
|
Device: Laser Utilisation Nano-second
Laser utilisation for tattoo depigmentation 1 session every month for a total of 3 sessions |
- Percentage of decrease of tattoos 2 months after the third session as compared to baseline on standardized pictures [ Time Frame: 2 month after the end of laser utilisation ]
- Evaluation of Pain with EVA test [ Time Frame: 2 months after one session of laser utilisation ]
- Evaluation of tolerance [ Time Frame: 2 months after one session of laser utilisation ]correlation between EVA test and dermatological clinical signs
- satisfaction evaluation of depigmanetation tattoo [ Time Frame: 2 months after one session of laser utilisation ]satisfaction tests
- Skin biopsies [ Time Frame: immediately after treatment ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Black tattoos with surface between 10 and 100 cm²
- Skin type I to VI
Exclusion Criteria:
- Childbearing age women
- Active dermatosis located on the tattoo
- Personal history of hypertrophic scars or keloids
- Pigmentary or vascular lesions located on the tattoo
- Subject taking oral steroid or retinoid or have any risk of delayed healing problems
- Acquired or hereditary conditions that could leead to a delayed healing
- Allergy to xylocaine, prilocaine or lidocaine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03386760
| Contact: Thierry PASSERON, PhD | +33492036488 | passeron.t@chu-nice.fr |
| France | |
| CHU de Nice - Dermatologie - Hôpital Archet | Recruiting |
| Nice, France, 06200 | |
| Contact: Thierry PASSERON, PhD +33492036488 passeron.t@chu-nice.fr | |
| Responsible Party: | Centre Hospitalier Universitaire de Nice |
| ClinicalTrials.gov Identifier: | NCT03386760 |
| Other Study ID Numbers: |
17-PP-07 |
| First Posted: | December 29, 2017 Key Record Dates |
| Last Update Posted: | August 12, 2019 |
| Last Verified: | August 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
tattoo |

